Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Total Non-Current Liabilities (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $22.0 million as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 3.21% year-over-year to $22.0 million; the TTM value through Mar 2026 reached $22.0 million, up 3.21%, while the annual FY2025 figure was $17.2 million, 27.92% down from the prior year.
  • Total Non-Current Liabilities hit $22.0 million in Q1 2026 for Wave Life Sciences, up from $17.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $161.5 million in Q1 2023 and bottomed at $17.2 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $66.9 million, with a median of $38.3 million recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities soared 59.86% in 2023 and then plummeted 77.63% in 2024.
  • Wave Life Sciences' Total Non-Current Liabilities stood at $112.1 million in 2022, then plummeted by 63.42% to $41.0 million in 2023, then crashed by 41.8% to $23.9 million in 2024, then fell by 27.92% to $17.2 million in 2025, then grew by 27.79% to $22.0 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $22.0 million, $17.2 million, and $23.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.